1. Home
  2. CLBT vs BEAM Comparison

CLBT vs BEAM Comparison

Compare CLBT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellebrite DI Ltd.

CLBT

Cellebrite DI Ltd.

HOLD

Current Price

$13.70

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$30.26

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLBT
BEAM
Founded
1999
2017
Country
Israel
United States
Employees
1285
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CLBT
BEAM
Price
$13.70
$30.26
Analyst Decision
Strong Buy
Buy
Analyst Count
4
12
Target Price
$22.50
$50.75
AVG Volume (30 Days)
1.7M
2.0M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
N/A
$24,000.00
Revenue This Year
$21.45
N/A
Revenue Next Year
$17.47
$33.77
P/E Ratio
$45.29
N/A
Revenue Growth
N/A
33.33
52 Week Low
$11.03
$15.52
52 Week High
$19.98
$36.44

Technical Indicators

Market Signals
Indicator
CLBT
BEAM
Relative Strength Index (RSI) 55.80 56.47
Support Level $13.01 $25.84
Resistance Level $13.78 $32.01
Average True Range (ATR) 0.51 1.85
MACD 0.13 -0.03
Stochastic Oscillator 83.21 58.65

Price Performance

Historical Comparison
CLBT
BEAM

About CLBT Cellebrite DI Ltd.

Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: